InvestorsHub Logo
Followers 5
Posts 593
Boards Moderated 0
Alias Born 06/11/2010

Re: DewDiligence post# 41371

Monday, 12/16/2013 4:49:35 AM

Monday, December 16, 2013 4:49:35 AM

Post# of 80490
Standard criteria per which docs report SAEs is not the same thing as stand nonsense per which the FDA reported Iclusig SAEs. You are right.

Standard criteria for adverse events is not the same thing as a standard format for reporting them.

Have I ever talked about the so-called standard format? Never! Why are you changing the topic?

What really matters is the criterion rather than the format. As long as the standard criteria are followed, 12%, or TWELVE PERCENT in a nonstandard format makes no differences.

However, if standard criteria get violated, 12% can be exaggerated to 24% per stand nonsense, or TWENTY FOUR PERCENT in a standard format.

Michael J. Mauro, MD, Leader of the Myeloproliferative Diseases Program at Memorial Sloan-Kettering Cancer Center who was an investigator on both the drug’s Phase I and II trials, said that the different interpretation and calculation of rates of toxicity as reported by the manufacturer versus the FDA was concerning, given that everyone was looking at the same raw data. This is an example of the need for common parameters for calculating such risks, he said. “One can render different opinions on their impact and their weight, but there shouldn’t be different ways of interpreting the risks or different ways of categorizing them. That’s a lesson this experience has taught us.”
http://journals.lww.com/oncology-times/blog/onlinefirst/pages/post.aspx?PostID=902

When one analyst questioned the wisdom of publicly taking issue with US regulators, Ariad chief scientific officer Timothy P. Clackson said,We felt obligated to, in a very careful way, explain our understanding” of the clinical data because of fears the FDA “created a lot of confusion and questions” among doctors and patients.

When standard criteria get violated, a lot of confusion and questions arise.

I agree with Clackson. Ariad is obligated to stay with the standard. This is probably the so-called "fight with the FDA" Adam Feuerstein is talking about.

Unfortunately, the FDA came down hard on Ariad as observed by Crédit Suisse analyst Jason Kantor.

Berger needs to fight harder with the FDA and carefully explain what have happened in the courtroom.
----------
If Harvey Berger's legal team acts against the FDA, I will vote him for the greatest CEO of all time.
----------
Dew, please continue your exchange convincingly. I believe you can.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.